Patent · US Active

Neuroendocrine tumors

US11549148B2 · kind B2 · utility

0Cited by
3References
10Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 21, 2017
Grant dateJan 10, 2023
Priority date
Expiry dateJul 21, 2037

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC12Q2600/16
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The disclosure provides methods for the use of gene expression measurements to classify or identify neuroendocrine cancer in samples obtained from a subject in a clinical setting, such as in cases of formalin fixed, paraffin embedded (FFPE) samples.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.